RICHLAND, WASHINGTON – September 28, 2021 – The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131...
Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT RICHLAND, WASHINGTON – September 21, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options...
Record Full Year Revenue Fiscal Fourth Quarter Revenue Increased 19% Year-Over-Year RICHLAND, WASHINGTON – September 21, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...
Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body,...
Revenue Increased 10% Sequentially Record Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, WASHINGTON – May 13, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering...
Conference Call is Thursday, May 13 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – April 29, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today...
RICHLAND, WASHINGTON – April 13, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed Vice President, Sales and Marketing. CEO Lori Woods said Fort’s appointment...
RICHLAND, WASHINGTON – March 31, 2021 – A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray’s Cesium-131 brachytherapy found potential benefits that support further...
RICHLAND, WASHINGTON – March 3, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Chief Executive Officer Lori Woods will present at the Oppenheimer 31st Annual Healthcare Conference on...
RICHLAND, WASHINGTON – February 16, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Lisa Lauer has been appointed Vice President, Business Development. CEO Lori Woods says Lauer’s...
Revenue Increased 7% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 92% Year-Over-Year RICHLAND, WASHINGTON – February 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...
Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – February 5, 2021– Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
RICHLAND, Wash., February 4, 2021 - Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced the pricing of its public offering of 36,000,000 shares of its...